Bar Harbor Wealth Management Sells 1,139 Shares of Eli Lilly and Company $LLY

Bar Harbor Wealth Management trimmed its holdings in Eli Lilly and Company (NYSE:LLY) by 1.5% during the second quarter, HoldingsChannel.com reports. The firm owned 74,974 shares of the company’s stock after selling 1,139 shares during the period. Eli Lilly and Company makes up about 3.7% of Bar Harbor Wealth Management’s portfolio, making the stock its 4th biggest holding. Bar Harbor Wealth Management’s holdings in Eli Lilly and Company were worth $58,444,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. WestEnd Advisors LLC raised its position in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock valued at $26,000 after purchasing an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at approximately $27,000. Citizens National Bank Trust Department raised its position in shares of Eli Lilly and Company by 180.0% during the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock valued at $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. acquired a new stake in shares of Eli Lilly and Company during the 1st quarter valued at approximately $40,000. Finally, TD Capital Management LLC raised its position in shares of Eli Lilly and Company by 129.2% during the 1st quarter. TD Capital Management LLC now owns 55 shares of the company’s stock valued at $46,000 after acquiring an additional 31 shares in the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Up 0.2%

Shares of LLY stock opened at $845.55 on Thursday. The stock has a 50-day simple moving average of $738.69 and a 200 day simple moving average of $766.57. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $937.00. The stock has a market capitalization of $800.28 billion, a P/E ratio of 55.26, a P/E/G ratio of 1.18 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business had revenue of $15.56 billion during the quarter, compared to analysts’ expectations of $14.40 billion. During the same quarter last year, the business posted $3.92 earnings per share. The company’s quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald purchased 1,565 shares of the firm’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average price of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director directly owned 74,578 shares of the company’s stock, valued at $47,903,686.74. This trade represents a 2.14% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Jamere Jackson purchased 200 shares of the firm’s stock in a transaction that occurred on Friday, August 8th. The stock was bought at an average price of $639.56 per share, with a total value of $127,912.00. Following the transaction, the director directly owned 9,402 shares in the company, valued at $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock worth $2,894,841 over the last three months. Company insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

LLY has been the topic of several research reports. Morgan Stanley dropped their price target on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday, October 3rd. DZ Bank upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 14th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft lowered their price target on Eli Lilly and Company from $1,010.00 to $900.00 and set a “buy” rating on the stock in a report on Monday, August 11th. Finally, UBS Group lowered their price target on Eli Lilly and Company from $1,050.00 to $895.00 and set a “buy” rating on the stock in a report on Friday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and ten have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $943.00.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.